MGT 419 Suffolk University Librarian for Second Research Deliverable Discussion

User Generated


Business Finance

MGT 419

Suffolk University



using the survey result to finish research deliverable assignment. The survey result:

Have to use school library to do research first and then finish "Visited Librarian file". Then, finish research deliverable assignment.

Unformatted Attachment Preview

Visited Librarian for Second Research Deliverable Date of visit Name of librarian Signature of librarian Student name Key outcomes (in bullet form is sufficient) Research (2) Rubric Evaluation Area 1. Selection of sources (15%) • • 2. Breadth of Research (includes both primary and secondary research) (60%) Percentage relates to the total points available for this section 3. Depth of research (includes both primary and secondary research) (25%) 4. Citations 5% Exceeds Expectations Identified highly appropriate sources in a variety of formats (books, journals, electronic sources) • Meets Expectations Identified mostly appropriate sources in a variety of formats (books, journals, electronic sources) • Below Expectations Little attempt to balance formats (books, journals, electronic sources) Leveraged librarian to fully take advantage of the library databases for research • Used one source from the librarian’s talk • Over-reliance on the internet • Visited the librarian and got some value to deepen the research. • Did not visit the librarian. Expansive research 8 sources 93% 9+ 95+% Primary research an integral part of findings. • • • • Sufficient research 6 sources 83% 7 sources 88% Primary Research included and is of value • • Insufficient research under 3 or less sources 0 for this section 4 sources 75% 5 sources 80% Primary Research not included • Showed creativity in approaching the research enabling expansion or deepening of the research question • Research was very specific to the question and the gaps • Identified gaps where further research is required • Wrote notes including succinct key facts which directly answered all of the research questions • Were able to adapt the research question to answer the research question adequately Research was somewhat specific to the question and gaps Some gaps were identified Wrote notes which included facts that answered most of the research questions and were written in the student’s own words. • • • Cited most sources of information in APA format and documented sources to enable accuracy checking. Organized per column one with key findings mostly in depth • • • • • Cited all sources of information accurately in APA format to demonstrate the credibility and authority of the information presented and for use for the presentation/report. • Organized using date, source (or name of interviewer, key findings in depth, category, clear identification of gaps) Grade % /125 • • • • • • • • • • • Research question was answered somewhat Research was random or insufficiently tied to the question/gaps No gaps were identified Wrote notes which included irrelevant facts which did not answer the research questions. Cited most sources of information improperly and provided little or no supporting documentation to check accuracy. Information not organized ** note: everyone should visit the librarian to better leverage the library databases. You may do this individually or with other members of your team. The only exception is if you are solely responsible for the primary research for your group. Research Deliverable (2) Objective: To answer the client question with in depth research that challenges the researcher to look at the question from a variety of angles. To ensure breadth and depth of research. Format: Use the same format as research deliverable (1). Spelling, grammar, etc. are not graded. Please include your key findings organized as follows 1. List your team objective/overall question 2. List your specific tasks assigned for this deliverable 3. Describe your research with the following information (or use the secondary research notes document outline) o Date of research o List the gaps you identified in your first research deliverable and explain the research you found for these gaps. o The key findings by source in 2 - 3 sentences or bullets o Sources of information utilized in APA format. Include link if found online. o Include the key findings from your first research deliverable in 3-5 sentences or bullets 4. List the areas that you will not cover. This will be used in case the client asks a question in this area 5. Clearly identify/differentiate the research from your second deliverable. Details: Please summarize your key findings succinctly. What did you find in your research? What information did it give you? What is missing? Your findings should be thorough enough that I can clearly understand what you learned as well as useful enough that you can easily use them directly for your analysis/presentation preparation. Although volume of research was emphasized for the first deliverable, quality is more important here. You still need a quantity of research but this deliverable should be more focused on what you need specifically to draw conclusions. The second deliverable should address your gaps as well as any other additional information you found. Do not list a bibliography. Match the findings with the citation so that it is clear what you found where. Sample Student MGT 419 – Second Research Deliverable Due: **** Research Question: What is the size and nature of the large pharmaceuticals market here (e.g. how many companies are here and what research or business operations are taking place locally)? Which aspects of drug discovery are they current outsourcing and to where? What criteria do they use to determine what to outsource? What are their needs? What other areas are they considering outsourcing? Which aspects of international outsourcing are they currently uncomfortable with (e.g. potential opportunities for reverse sourcing)? Where can Large Biotech- add value? How might they take more of this outsourcing market? What’s the potential/opportunity? Research Categories: Competitors Customers • Pharma • Biotech International Industry • Pharma • Biotech Outsourcing Regulatory Not relevant to our question Categories Assigned: My research is predominately focused on market analysis and business opportunities in the area. These fall under the research categories of industry (pharma/biotech) and customers (pharma/biotech). Secondary Research Notes: Research Category: Customers –pharma/biotech Date of Research: **** Summary of Research: I did a scrub of LinkedIn profiles in an attempt to set up research interviews. I searched for people who worked for different pharma/biotech companies that had “outsourcing” or “procurement” in their job titles. Key Findings: • Most of the people who met my criteria worked in overseas operations for the firms. This supports the statement that Mike Earley made during our last client meeting – that the big pharma companies house their compounds overseas where they have more warehouse space and ship compounds to their U.S. labs on an as needed basis. Missing Information/Additional Questions: • Come up with a comprehensive list of names/titles/organizations for Large Biotech. This will help them identify contacts at these companies for business development. • Identify people who are part of the “compound management” group on LI. Citation and URL: Valastyan, L. (2011, April 12). Sample management sig. Retrieved from Page 1 of 8 Sample Student MGT 419 – Second Research Deliverable Due: **** Research Category: Customers; Industry Date of Research: **** Summary of Research: This article discusses a survey that was published on pharmaceutical compound management that looked at the current business practices, issues and trends. The survey had a specific focus on quality control. Key Findings: • Main issue in compound management = sample integrity • Biggest bottleneck =retrieval of compounds and capacity • Mean size of a compound library was expected to be 1.8M in large pharma and 1.25M for small pharma by 2008. • CM facilities place a huge importance on sample integrity – specifically, the degree to which the structure of the compound is what it’s supposed to be as labeled; the purity of the sample; and, the concentration of the sample. Water uptake is the main reason sample integrity is compromised. As such, quality control measures to assess the integrity of samples is a major priority for CM facilities. • Retrieval rates in automated CM is important because it’ll determine how quickly a company will receive their samples. This is based on the size of the order, whether items are retrieved as entire racks or are individually cherry-picked, the number of times on a tray and whether alternative vessels are available for use. Additionally, items that are retrieved frequently are easier to find. • Flexibility is important in order to develop new routes to integrate into the process. Non-invasive technologies that monitor samples and life cycles are important. Also, increasing the size of the collection to be more diverse and targeted to specific disease-states with faster turnaround times. Missing Information/Additional Questions: • Updated numbers?? Citation and URL: Comley, J. (2005). Compound management in pursuit of sample integrity.. Retrieved from Research Category: Customers; Large Biotech; Outsourcing Date of Research: **** Summary of Research: This book discusses the key features of compound management facilities, IT infrastructure supporting CM facilities and the reasons for outsourcing sample management. Key Findings: KEY FEATURES OF CM IT SYSTEMS: • CM IT systems must have inventory features; track receipt; creation; movement; and, dispatch of samples. The more advance systems also provide processes that guide the sample manager through a workflow when fulfilling requests. • The system must have an inventory view and order management components. • Databases recognize labware based on barcodes which will tell the sample manager the type of the compound, amount stored and location of the item. • Sample manager must have a means of importing and editing inventory items. • Dispatch operations tell the sample manager where the item has been dispatched to and updates the system with the new location. It could also Page 2 of 8 Sample Student • MGT 419 – Second Research Deliverable Due: **** feature automated receipt systems that send a delivery note to recipients. Reports and metrics related to process throughput, current stock and restock items, turnaround time and machine utilization. OUTSOURCING • Total pharma biotech and outsource market is estimated at $33B and is expected to reach $48B. R&D outsourcing is approximately 50% of the total market. • Main benefits of outsourcing are economic and organizational; outsourcing provides access to technology and capacity without the need for investment in equipment or personnel. It also offers flexibility. It provides access to the latest technology and capacity while avoiding capitcal investment and reducing depreciation costs. • Companies who choose to outsource must consider their own resources, how the vendor will provide cost savings, physical resources and human resources. • Successful outsourcing provides cost savings, increased operational efficiency, and optimization or resource allocation. • Outsourcing is about building LT relationships with the vendor built on quality, service, knowledge, culture and cost. • Outsourcing entire compound management activities to a third-party is rare for major pharma companies. However, M&A reorganization usually means that compound collections need to be moved between sites or brought together into a single collection, so using a third-party, neutral, outsourcing path may help prevent internal management conflicts. KEY COMPETENCIES FOR CM VENDORS: • Privacy protection for samples • Robust chain of custody procedures for samples • Appropriate conditions for sample storage • Procedures to comply with regulations • Sample coding Missing Information/Additional Questions: Citation and URL: Wigglesworth, M., & Wood, T. (****). Management of chemical and biological samples for screening applications. (pp. 265-272, 367-378). Germany: John Wiley & Sons. Retrieved from library pharma&source=bl&ots=GVyvZp3JuZ&sig=9h2XXJJRPgQt2plmn7CDhVWX8jY&hl=en&sa=X&ei=F0SgUPafELGw0AH0yYFY&ved=0CFcQ6AEwBTg K Related interview - Page 3 of 8 Sample Student MGT 419 – Second Research Deliverable Due: **** Research Category: Industry – Pharma/Biotech Date of Research: **** Summary of Research: This article discusses the safety and efficacy of biosimilar molecules that are used to develop generic versions of drugs. The small molecules that are being copied to create these biosimilars are not precise because they’re being made from human/animal agents rather than chemical agents. Key Findings: • There is a huge area of quality control that Large Biotech needs to focus on in the bioactive molecule segment. • Slight variations in biosimilar molecules are a huge concern because they could essentially change the way the drug works. • This is an opportunity for Large Biotech to increase the testing they do on biosimilar agents in order to make it as a close of a match as possible to the target molecule, which would position Large Biotech as an industry leader in this arena. • This is directly related to Large Biotech’s core competency areas. Missing Information/Additional Questions: Citation and URL: Rosenthal, M. (****, February 1). Clinicians concerned about safety, efficacy of biosimilar drugs. Modern Medicine, Retrieved from Research Category: Industry – Pharma/Biotech, Regulatory Date of Research: **** Summary of Research: As a result of the Patient Protection and Affordable Care Act, the FDA has placed restrictions on biosimilar agents and generic drug development. This is an area that impacts Large Biotech’s client base. Key Findings: • There are much stronger regulations on biosimilars as a result of the ACA. Large Biotech may have an opportunity to open up the pipeline to companies who specialize in developing biosimilar drugs. • Large Biotech could partner with the companies to create the biosimilar agents by offering their compound management solutions at a discounted rate. Additionally, they could offer testing services in order to speed up the drug discovery timeline. Missing Information/Additional Questions: Citation and URL: Edlin, M. (2011, August 15). Approval pathway for biosimilars still evolving. Drug Topics, 155(8), Retrieved from Page 4 of 8 Sample Student MGT 419 – Second Research Deliverable Due: **** Research Category: Customers - Pharma Date of Research: **** Summary of Research: Link to Pfizer’s Small Molecule Therapeutics Discovery R&D work. Provides information on current initiatives and partnership opportunities. Key Findings: • Pfizer creates alliances with other companies to advance their R&D work. This is an opportunity for Large Biotech to determine who is partnering with Pfizer in these areas. Since they already have an agreement with Pfizer’s Boston laboratory, Large Biotech could offer its services at a discounted price to those organizations in partnership with Pfizer. • Pfizer is not looking for a partnership with “compound libraries with no or little track record of finding hits” – could Large Biotech add their success record to their value proposition to better position them in the market? Missing Information/Additional Questions: • Who is currently partnering with Pfizer? Citation and URL: Research Category: Customers – Pharma Date of Research: **** Summary of Research: This press release is regarding the $100M investment AstraZeneca made in 2007 to expand their facility in Waltham, MA. The second article discusses the new partnership AZ has with the Broad Institute in Cambridge to create a gigantic compound library (over 100,000 compounds) for use in R&D. Key Findings: • The MA facility has seen major success in the discovery of drugs to treat three different cancers. • There has been a decline in the amount of new antibacterial agents that are entering the market. AZ is focused on creating new agents for worldwide use – could Large Biotech store these on location for them and sell as a middle-man to companies that want to purchase them from AZ? • As part of the Broad Institute/AZ partnership, the Broad is testing the drugs in their facility with the hopes of creating drugs that can be used by patients. Is it more expensive for the Broad to keep these compounds in house? Missing Information/Additional Questions: • Does AZ manage their compound inventories in-house? Is the Broad Institute managing all of their compounds? How does the partnership affect the AZ R&D facility in Waltham? Citation and URL: Page 5 of 8 Sample Student MGT 419 – Second Research Deliverable Due: **** Research Category: Customers - Pharma Date of Research: **** Summary of Research: Information on Pfizer’s Groton, CT facility where they house compounds and have a BioBank. Key Findings: • For the most part, it appears as though Pfizer does most of their compound management on-site in Groton, CT. They have a Liquid Compound Management and Distribution center where they are able to fulfill thousands of requests for compounds. However, the client has told us that they recently secured Pfizer as a client – are they serving just the Boston R&D facility? How can we use their work for Pfizer to secure other clients who have HQs in other states? • Pfizer’s BioBank is cold storage for bioactive molecules. These molecules have very specific environments they need to live in or else they spoil and are useless. Does Large Biotech have cold storage? They would also need cold storage transport if they were shipping items to local R&D facilities. Missing Information/Additional Questions: Citation and URL: Research Category: Customers – Pharma Date of Research: November 8 , **** Summary of Research: A press release on the collaboration between AstraZeneca and Pharmacopeia which will shift their focus from compound libraries to drug discovery to identify small molecule compounds against a specific drug target. Key Findings: • Pharmacopeia is providing expertise in identifying small molecule lead compounds for AZ. As part of the partnership, Pharmacopeia is entitled to receive payment for the successful identification of these compounds. This partnership will help AZ expand its product line and quality of drugs for specific disease states. • The partnership will utilize AZ’s multimillion compound sample library and screening technology. Missing Information/Additional Questions: • Many pharma companies create partnerships with smaller firms to expand their R&D and product offerings. This is an opportunity for Large Biotech to get their foot in the door with big pharma companies by identifying companies that are partners. Citation and URL: Page 6 of 8 Sample Student MGT 419 – Second Research Deliverable Due: **** Research Category: Customers Date of Research: **** Summary of Research: Conference hosted on Compound Management. Features names/titles of presenters and sponsors. Key Findings: • Company A Institute is based in Needham. This may be an opportunity for Large Biotech to collaborate with CHI to present at their conferences. May be able to get an attendee list from recent events by calling. • CHI puts on a ton of events that are right in Large Biotech’s sweet spot. • By attending these events either as a speaker or a participant, Large Biotech can learn about what their customers want and what their competitors are doing. Missing Information/Additional Questions: • Why doesn’t Large Biotech attend/sponsor these events? If they presented at these conferences, they would gain major visibility with their target market. Citation and URL: (2010). The compound management forum, Providence, RI. Retrieved from Similar conference – useful for client list: &utm_content=10/02/12&mac=11314.006PR Research Category: Customers – Pharma/Biotech Date of Research: **** Summary of Research: This article discusses the wants/needs of Compound and Sample Managers. These are reflective of the wants/needs of Large Biotech’s clients in the big pharma industry. Key Findings: • Access to a large library of HQ compounds and samples and automated technology will enable successful drug discovery. • Since big pharma companies are handling millions of chemical compounds and samples, the logistics of storing and retrieving the compounds are more critical than ever. • High Throughput Screening is becoming a thing of the past and companies are moving to more selective screening processes which conserves compounds. The process is becoming leaner so libraries need to become more efficient in order to hit the target. • BioFocus and RTS Group are competitors for Large Biotech. • PRIMARY CONCERNS FOR Large BiotechMPLE MANAGERS – GRAPH: Page 7 of 8 Sample Student MGT 419 – Second Research Deliverable Due: **** Missing Information/Additional Questions: Citation and URL: Expanding sample libraries tops the wish list for compound and sample managers. (****, May 21). Retrieved from Research Category: Customers; Industry Date of Research: **** Summary of Research: This journal article discusses the trend of outsourcing compound libraries and assess the value big pharma companies place on this business decision. Key Findings: • Large pharma companies are facing challenges in managing compounds due to M&A. This is because mergers result in compounds being held various locations with different technologies and non-consolidated databases. The expense of managing more than one library has forced pharma companies to outsource this function. • Compound storage is expensive! On top of the capital investments for storage, lab space and equipment, there are also human capital costs and costs related to technologies. This causes downtime within their preexisting system and impacts other R&D activities. • Successful CM systems have the following characteristics: o Easy and accurate accessibility o Compound integrity o Efficient usage (less waste!) o Flexibility to adapt to demand o Dynamism within the collection o Availability and integrity of inventory data • Three main requirements when considering outsourcing inventory: o Security of the samples o Robust and reliable IT infrastructure (with firewalls) o Back up/disaster recovery plan • SOURCING THE RIGHT PARTNER - Missing Information/Additional Questions: Citation and URL: Boucharens, S. (2010). Outsourcing compound inventory trend or real benefits?. Pharmaceutical Outsourcing, Retrieved from Page 8 of 8
Purchase answer to see full attachment
User generated content is uploaded by users for the purposes of learning and should be used following Studypool's honor code & terms of service.

Explanation & Answer

incase of revision, let me know. was nice working with you.


Research Deliverable 2

Student’s Name
Institutional Affiliation
Instructor’s Name


Research Deliverable 2
Two primary objectives will be given priority in this particular research. The first one
will be to find out the purchasing habits of coffee among the consumers. This will mainly
concern what exactly motivates the consumers to carry out their purchases, where they take their
coffee from, among other considerations. The second objective of the research will be to
examine the consumption rate and how often individuals consume coffee.
The following were specific tasks that were assigned for this particular research deliverable.
1. Recording down the specific findings that were gotten from the survey.
2. Finding out the percentage responses as revealed from the study.
3. Organizing sources so that only relevant references are used to support the survey
4. Establishing the survey results to be used.
Research Description
Date of research: November 9, 2020
Gaps Identified from the first research.
There were specific gaps that were identified in the research. The first gap that will be
addressed is that early research did not specify the number of participants involved in the study.
This was not to as specifically which group of people were involved in carrying out the survey.
The other gap identified is that the research was based only on the company but not directly on
the consumers.
Research category: consumption behavior


Summary: I was more concerned with the consumption behavior. Journal articles were the
best option.
Key findings
Most people drink coffee due to the health benefits that are attached to it. Most of the health
benefits have motivated them to purchase it at least once in a day. They are more willing to
pay as they understand what it means to their general health. Due to its benefits, many
individuals have established a habit of consuming daily
Missing information
Citation and url
Samoggia, A., & Riedel, B. (2019). Consumers’ perceptions of coffee health benefits and
motives for coffee consumption and purchasing. Nutrients, 11(3), 653.
Sheriff, N. M., Ismail, H., Bakar, Z. I. A., & Damain, D. (2016). Coffee marketing: What
matters to coffee drinkers?. Jurnal Intelek, 10(2).

Research category: Consumption population
Summary: The article considers to look at the population which consumes coffee in the
United States
Key findings
USA population makes the highest coffee consumption target market. The...

I use Studypool every time I need help studying, and it never disappoints.


Similar Content

Related Tags